Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
-
We report a case of encephalopathy progressing to brain death in a pediatric patient with confirmed infection with novel influenza H1N1. Although neurologic dysfunction associated with H1N1 has been described, we believe this to be the first published report of brain death associated with H1N1 infection.
-
Australian Indigenous children are the only population worldwide to receive the 7-valent pneumococcal conjugate vaccine (7vPCV) at 2, 4, and 6 months of age and the 23-valent pneumococcal polysaccharide vaccine (23vPPV) at 18 months of age. We evaluated this program's effectiveness in reducing the risk of hospitalization for acute lower respiratory tract infection (ALRI) in Northern Territory (NT) Indigenous children aged 5-23 months. ⋯ Our results suggest an increased risk of ALRI requiring hospitalization after pneumococcal vaccination, particularly after receipt of the 23vPPV booster. The use of the 23vPPV booster should be reevaluated.
-
Case Reports
Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.
The safety of high-dose oseltamivir during treatment of 2009 H1N1 influenza A infection for critically ill patients is unknown. Here we report on a case patient with severe, delayed-onset neuropsychiatric symptoms after administration of high-dose oseltamivir. Clinicians should be vigilant to the possible increased risk of complications associated with high-dose oseltamivir therapy for 2009 H1N1 influenza A infection.